Abstract
Author(s): Eirteham Saeed Raheem, Zahraa Emad Hussein, Saif Sameer Shmto, Bahaa K. AL-Ghanimi, Saif M. Hassan*
Background: Secondary Hyperparathyroidism (sHPT) is a common complication in patients with chronic kidney failure, resulting from an imbalance in calcium and phosphate levels due to renal dysfunction. L-Carnitine deficiency, a key compound in energy metabolism and mitochondrial function, is believed to contribute to these metabolic disturbances. Objectives: This study aims to evaluate the relationship between L-Carnitine deficiency and secondary hyperparathyroidism, focusing on its impact on calcium and phosphate levels in patients with kidney failure undergoing hemodialysis. Material and methods: The study included forty women with chronic kidney failure undergoing dialysis, aged between 21 and 62 years. The study was conducted on the same group and compared before and after treatment. Samples were collected for each group in August 2024 and March 2025. PTH, calcium, and phosphate levels were analyzed for the group of patients before treatment and 3-4 months after treatment. Results: The findings revealed a significant association between L-Carnitine deficiency and elevated PTH levels, suggesting an exacerbation of secondary hyperparathyroidism. Additionally, women with L-Carnitine deficiency exhibited lower calcium levels and significantly higher phosphate levels, potentially increasing the risk of mineral and bone disorders related to kidney disease. Conclusion: This study suggests that L-Carnitine deficiency may contribute to calcium and phosphate imbalances, leading to the progression of sHPT in patients with kidney failure. Correcting L-Carnitine deficiency through supplementation could be a potential strategy for improving mineral and bone disorder management in these patients. Further research is needed to determine the clinical benefits of L-Carnitine therapy in kidney failure women.